T lymphocytes conditioned with Interferon β induce membrane and soluble VCAM on human brain endothelial cells

被引:32
作者
Calabresi, PA
Prat, A
Biernacki, K
Rollins, J
Antel, JP
机构
[1] Brown Univ, Rhode Isl Hosp, Dept Clin Neurosci, Providence, RI 02903 USA
[2] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
基金
英国医学研究理事会;
关键词
VCAM-1; blood-brain barrier; interferon beta; multiple sclerosis; leukocyte;
D O I
10.1016/S0165-5728(01)00253-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vascular cell adhesion molecule (VCAM)-1 plays a critical role in mediating inflammatory cell adhesion and migration. Factors regulating the expression of membrane (m)VCAM and its cleaved counterpart soluble (s)VCAM are poorly understood. We previously demonstrated that serum sVCAM levels are increased in multiple sclerosis (MS) patients treated with interferon beta 1b (IFN beta 1b), which correlated with a reduction in gadolinium enhancing lesions on magnetic resonance imaging. However, subsequent studies have shown that IFN beta does not directly induce VCAM expression on endothelial cells. We demonstrate here that co-culture with IFN beta -conditioned T cells induces mVCAM on human brain endothelial cells (HBEC). Further, rapid shedding of sVCAM occurs, which mirrors the response after in vivo IFN beta treatment. The VCAM induction is mediated partially through tumor necrosis factor (TNF)alpha and can be abrogated by sTNF receptor. VCAM could also be induced on astroglioma lines using IFN beta -conditioned T cells, which suggests the effect is not specific for HBEC. Kinetic studies demonstrated an increase in the sVCAM to mVCAM ratio over time, which may contribute to the ultimate therapeutic effect of IFN beta in patients. These data have important implications for understanding the events occurring at the blood brain barrier in vivo, and for determining the mechanism of action of IFN beta in MS. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 31 条
  • [1] [Anonymous], 1999, Neurology, V53, P457
  • [2] Barone C M, 1993, J Craniofac Surg, V4, P177, DOI 10.1097/00001665-199307000-00013
  • [3] BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003
  • [4] VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta
    Calabresi, PA
    Pelfrey, CM
    Tranquill, LR
    Maloni, H
    McFarland, HF
    [J]. NEUROLOGY, 1997, 49 (04) : 1111 - 1116
  • [5] Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b
    Calabresi, PA
    Tranquill, LR
    Dambrosia, JM
    Stone, LA
    Maloni, H
    Bash, CN
    Frank, JA
    McFarland, HF
    [J]. ANNALS OF NEUROLOGY, 1997, 41 (05) : 669 - 674
  • [6] THE ADHESION MOLECULE AND CYTOKINE PROFILE OF MULTIPLE-SCLEROSIS LESIONS
    CANNELLA, B
    RAINE, CS
    [J]. ANNALS OF NEUROLOGY, 1995, 37 (04) : 424 - 435
  • [7] CARLOS TM, 1994, BLOOD, V84, P2068
  • [8] Microglial production of TNF-alpha is induced by activated T lymphocytes - Involvement of VLA-4 and inhibition by interferon beta-1b
    Chabot, S
    Williams, G
    Yong, VW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (03) : 604 - 612
  • [9] The effect of interferon beta-1 beta on lymphocyte endothelial cell adhesion
    DhibJalbut, S
    Jiang, H
    Williams, GJ
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1996, 71 (1-2) : 215 - 222
  • [10] CIRCULATING, SOLUBLE ADHESION PROTEINS IN CEREBROSPINAL-FLUID AND SERUM OF PATIENTS WITH MULTIPLE-SCLEROSIS - CORRELATION WITH CLINICAL ACTIVITY
    DOREDUFFY, P
    NEWMAN, W
    BALABANOV, R
    LISAK, RP
    MAINOLFI, E
    ROTHLEIN, R
    PETERSON, M
    [J]. ANNALS OF NEUROLOGY, 1995, 37 (01) : 55 - 62